Annual EBIT
-$190.51 M
+$117.88 M+38.22%
December 31, 2023
Summary
- As of February 12, 2025, FATE annual earnings before interest & taxes is -$190.51 million, with the most recent change of +$117.88 million (+38.22%) on December 31, 2023.
- During the last 3 years, FATE annual EBIT has fallen by -$62.43 million (-48.74%).
- FATE annual EBIT is now -1332.41% below its all-time high of -$13.30 million, reached on December 31, 2011.
Performance
FATE EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$52.38 M
-$7.29 M-16.18%
September 30, 2024
Summary
- As of February 12, 2025, FATE quarterly earnings before interest & taxes is -$52.38 million, with the most recent change of -$7.29 million (-16.18%) on September 30, 2024.
- Over the past year, FATE quarterly EBIT has dropped by -$1.10 million (-2.14%).
- FATE quarterly EBIT is now -1419.05% below its all-time high of -$3.45 million, reached on March 31, 2013.
Performance
FATE Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$196.60 M
-$1.10 M-0.56%
September 30, 2024
Summary
- As of February 12, 2025, FATE TTM earnings before interest & taxes is -$196.60 million, with the most recent change of -$1.10 million (-0.56%) on September 30, 2024.
- Over the past year, FATE TTM EBIT has increased by +$10.25 million (+4.96%).
- FATE TTM EBIT is now -5286.38% below its all-time high of -$3.65 million, reached on September 30, 2012.
Performance
FATE TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
FATE EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +38.2% | -2.1% | +5.0% |
| 3 y3 years | -48.7% | -83.2% | +25.1% |
| 5 y5 years | -193.5% | -51.9% | -76.3% |
FATE EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +38.2% | -83.2% | +39.4% | -3.2% | +37.3% |
| 5 y | 5-year | -97.6% | +38.2% | -88.7% | +39.4% | -104.0% | +37.3% |
| alltime | all time | -1332.4% | +38.2% | -1419.0% | +39.4% | -5286.4% | +37.3% |
Fate Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$52.38 M(+16.2%) | -$196.60 M(+0.6%) |
| Jun 2024 | - | -$45.08 M(-11.7%) | -$195.50 M(-8.2%) |
| Mar 2024 | - | -$51.07 M(+6.2%) | -$212.99 M(+11.8%) |
| Dec 2023 | -$190.51 M(-38.2%) | -$48.08 M(-6.2%) | -$190.51 M(-7.9%) |
| Sep 2023 | - | -$51.28 M(-18.0%) | -$206.85 M(-14.5%) |
| Jun 2023 | - | -$62.56 M(+118.8%) | -$241.97 M(-7.8%) |
| Mar 2023 | - | -$28.59 M(-55.6%) | -$262.51 M(-14.9%) |
| Dec 2022 | -$308.39 M(+42.1%) | -$64.42 M(-25.4%) | -$308.39 M(-1.6%) |
| Sep 2022 | - | -$86.39 M(+3.9%) | -$313.35 M(+11.3%) |
| Jun 2022 | - | -$83.11 M(+11.6%) | -$281.58 M(+14.8%) |
| Mar 2022 | - | -$74.47 M(+7.3%) | -$245.25 M(+13.0%) |
| Dec 2021 | -$216.99 M(+69.4%) | -$69.38 M(+27.0%) | -$216.99 M(+19.9%) |
| Sep 2021 | - | -$54.62 M(+16.8%) | -$181.01 M(+14.7%) |
| Jun 2021 | - | -$46.78 M(+1.2%) | -$157.88 M(+12.9%) |
| Mar 2021 | - | -$46.21 M(+38.4%) | -$139.80 M(+9.1%) |
| Dec 2020 | -$128.09 M(+32.9%) | -$33.40 M(+6.1%) | -$128.09 M(+4.6%) |
| Sep 2020 | - | -$31.49 M(+9.7%) | -$122.45 M(+4.5%) |
| Jun 2020 | - | -$28.71 M(-16.8%) | -$117.17 M(+5.1%) |
| Mar 2020 | - | -$34.49 M(+24.2%) | -$111.53 M(+15.7%) |
| Dec 2019 | -$96.40 M(+48.5%) | -$27.76 M(+5.9%) | -$96.40 M(+14.4%) |
| Sep 2019 | - | -$26.21 M(+13.6%) | -$84.23 M(+13.3%) |
| Jun 2019 | - | -$23.07 M(+19.2%) | -$74.37 M(+5.4%) |
| Mar 2019 | - | -$19.36 M(+24.1%) | -$70.53 M(+8.7%) |
| Dec 2018 | -$64.90 M | -$15.60 M(-4.6%) | -$64.90 M(+5.7%) |
| Sep 2018 | - | -$16.35 M(-15.0%) | -$61.39 M(+10.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2018 | - | -$19.23 M(+40.1%) | -$55.34 M(+21.5%) |
| Mar 2018 | - | -$13.72 M(+13.6%) | -$45.55 M(+9.3%) |
| Dec 2017 | -$41.68 M(+31.0%) | -$12.09 M(+17.3%) | -$41.68 M(+12.0%) |
| Sep 2017 | - | -$10.31 M(+9.3%) | -$37.21 M(+5.5%) |
| Jun 2017 | - | -$9.43 M(-4.3%) | -$35.26 M(+4.3%) |
| Mar 2017 | - | -$9.86 M(+29.5%) | -$33.80 M(+6.2%) |
| Dec 2016 | -$31.82 M(+14.6%) | -$7.61 M(-8.9%) | -$31.82 M(+2.3%) |
| Sep 2016 | - | -$8.35 M(+4.8%) | -$31.12 M(+7.0%) |
| Jun 2016 | - | -$7.97 M(+1.1%) | -$29.09 M(+2.7%) |
| Mar 2016 | - | -$7.89 M(+14.2%) | -$28.34 M(+2.0%) |
| Dec 2015 | -$27.77 M(+9.6%) | -$6.91 M(+9.3%) | -$27.77 M(+3.6%) |
| Sep 2015 | - | -$6.32 M(-12.4%) | -$26.80 M(-0.3%) |
| Jun 2015 | - | -$7.22 M(-1.5%) | -$26.90 M(+4.6%) |
| Mar 2015 | - | -$7.32 M(+23.2%) | -$25.72 M(+1.5%) |
| Dec 2014 | -$25.33 M(+26.1%) | -$5.94 M(-7.4%) | -$25.33 M(+2.3%) |
| Sep 2014 | - | -$6.42 M(+6.2%) | -$24.75 M(+2.4%) |
| Jun 2014 | - | -$6.04 M(-12.9%) | -$24.18 M(+2.5%) |
| Mar 2014 | - | -$6.94 M(+29.4%) | -$23.59 M(+17.4%) |
| Dec 2013 | -$20.10 M(+46.1%) | -$5.36 M(-8.2%) | -$20.10 M(+5.9%) |
| Sep 2013 | - | -$5.84 M(+7.3%) | -$18.98 M(+13.1%) |
| Jun 2013 | - | -$5.45 M(+57.9%) | -$16.78 M(+48.0%) |
| Mar 2013 | - | -$3.45 M(-18.7%) | -$11.34 M(+43.7%) |
| Dec 2012 | -$13.75 M(+3.4%) | -$4.24 M(+16.1%) | -$7.89 M(+116.1%) |
| Sep 2012 | - | -$3.65 M | -$3.65 M |
| Dec 2011 | -$13.30 M | - | - |
FAQ
- What is Fate Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Fate Therapeutics?
- What is Fate Therapeutics annual EBIT year-on-year change?
- What is Fate Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Fate Therapeutics?
- What is Fate Therapeutics quarterly EBIT year-on-year change?
- What is Fate Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Fate Therapeutics?
- What is Fate Therapeutics TTM EBIT year-on-year change?
What is Fate Therapeutics annual earnings before interest & taxes?
The current annual EBIT of FATE is -$190.51 M
What is the all time high annual EBIT for Fate Therapeutics?
Fate Therapeutics all-time high annual earnings before interest & taxes is -$13.30 M
What is Fate Therapeutics annual EBIT year-on-year change?
Over the past year, FATE annual earnings before interest & taxes has changed by +$117.88 M (+38.22%)
What is Fate Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of FATE is -$52.38 M
What is the all time high quarterly EBIT for Fate Therapeutics?
Fate Therapeutics all-time high quarterly earnings before interest & taxes is -$3.45 M
What is Fate Therapeutics quarterly EBIT year-on-year change?
Over the past year, FATE quarterly earnings before interest & taxes has changed by -$1.10 M (-2.14%)
What is Fate Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of FATE is -$196.60 M
What is the all time high TTM EBIT for Fate Therapeutics?
Fate Therapeutics all-time high TTM earnings before interest & taxes is -$3.65 M
What is Fate Therapeutics TTM EBIT year-on-year change?
Over the past year, FATE TTM earnings before interest & taxes has changed by +$10.25 M (+4.96%)